# Moderna Pays $2.25 Billion to Settle mRNA Vaccine Patent Fight With Arbutus and Genevant

*2026-03-04 22:02 UTC · Science · 1 min read*

> Moderna settles $2.25B patent dispute over lipid nanoparticle technology used in its mRNA COVID vaccines.

Moderna has agreed to pay up to $2.25 billion to Arbutus Biopharma and Roivant subsidiary Genevant Sciences, ending a years-long legal battle over the lipid nanoparticle (LNP) technology critical to its mRNA COVID-19 vaccines. The settlement includes $950 million upfront in July 2026, with an additional $1.3 billion contingent on the outcome of a separate legal appeal.

The dispute centered on the fatty shells that deliver mRNA into human cells — a technology pioneered by Arbutus that Moderna used without a license. Under the deal, Moderna receives a global non-exclusive license for LNP delivery in infectious-disease mRNA vaccines and will owe no future royalties. Moderna shares jumped over 15% on the news, driving the stock up more than 95% year-to-date in 2026.

Arbutus and Genevant still have a separate ongoing patent lawsuit against Pfizer and BioNTech over the same LNP technology used in their competing COVID vaccine.

## Sources

- [biopharmadive.com](https://www.biopharmadive.com/news/moderna-roivant-arbutus-genevant-patent-settlement-mrna-vaccines/813792/)
- [statnews.com](https://www.statnews.com/2026/03/03/moderna-settles-covid-vaccine-suit-roivant/)

---
TechTools News · https://techtools.cz/tools/news/article/572-moderna-pays-2-25-billion-to-settle-mrna-vaccine-patent-fight-with-arbutus-and
Česká verze: https://techtools.cz/tools/news/clanek/578-moderna-zaplati-2-25-miliardy-dolaru-za-urovnani-patentoveho-sporu-o-mrna
